Justifications for differentiated approach in correction of some changes of the immunologic disorders in patients with rapidly progressing generalized parodontitis with different drug susceptibility of the parodontal bacteria
DOI:
https://doi.org/10.26641/2307-0404.2020.4.221409Ключові слова:
rapidly progressive generalized periodontitis, infectious and inflammatory process, drug-resistant microflora, immunityАнотація
Rapidly progressing generalized periodontitis (RPGP) still remains an extremely important medical problem, despite certain achievements in solving most of the issues of etiology, pathogenesis and treatment. The study included 102 patients with rapidly progressing periodontitis of I-II and II-III degrees of severity, with ineffective and inconsistent results of previous treatment who were examined and treated in the clinic of the Department of Surgical Dentistry, Periodontics and Implantology of the SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine». On the basis of the diagnostic and therapeutic measures carried out, it was established that, in patients with rapidly progressing generalized periodontitis, the formation of various drug sensitivity in periodontopathogenic microorganisms to protocol antibacterial therapy is closely associated with immunological protocol diseases. The presence of drug-resistant bacteria in the periodontal tissues is combined with a more pronounced immunodeficiency in the mechanisms of systemic and local protection than when the lesions are colonized by drug-sensitive periodontal microorganisms. The revealed features of immunity disorders in patients with RPGP with drug-resistant infection to conventional antibiotic therapy are manifested by a decrease in CD3+ lymphocytes, cells with cytostatic activity (CD4+, CD16+) expressing receptors for the activation of lymphocytes CD25+, HLA-DR and apoptosis CD95+), against the background of a slight increase in CD20+, CD116+, CD54+, significant inhibition of the synthesis of SIgA, IgM, α-INF, γ-INF; a pronounced increase in the production of pro-inflammatory cytokines IL-1β and TNF-α. The need for a differentiated approach in the correction of immunological disorders in patients with RPGP depending on the detected sensitivity and resistance of periodontal pathogenic bacteria to the protocol generally accepted antibacterial therapy has been clearly proved; this provides a faster relief of the infectious and inflammatory process (on average on 3.6±0.2 day) in more than 90% of cases, normalization of the parameters of immunological reactivity in 93.3% of the observed and stable clinical remission of the disease.Посилання
Antomonov M. [Mathematical processing and analysis of biomedical data]. 2nd ed. Kyiv: MIC «Medinform»; 2018;579. ISBN 978-966-409-202-6. Russian.
Elovikova TM. Gaisina EF. Prihodkin. [The use of antibacterial drugs for aggressive forms of periodontitis]. Problemy stomatologii. 2019;15(1):10-15. Russian.
doi: https://doi.org/10.18481/2077-7566-2019-15-1-10-15.
Kopeckii IS. Pobozh'eva LV. Sheveljuk JuV. [Aggressive periodontitis: clinical and microbiological aspects of development]. Lechebnoe delo. 2019;1:7-13. doi: https://doi.org/10.24411/2071-5315-2019-12084. Russian.
Leonova EV. [Aggressive periodontitis: characteristics. clinical picture. diagnostics. treatment algorithms]. Clinical observation. Medi izdatel'stvo. 2018;1(78):34-36. Russian.
Mashhenko IS. Gudaryan AA. Dorogina AS. [The reasons for the resistance of the main periodontal pathogens to antibiotic therapy in patients with rapidly progressive generalized periodontitis]. Vіsnik stomatology. 2013;4:35-41. Russian.
Abe FC. Bergamaschi CC. Figueiró MF. Lopes LC. Resistance profile to antimicrobial agents in the main circulating bacteria isolated from acute periodontal and endodontic infections in Latin America (MICROBE-DENT): A systematic review protocol. Medicine (Baltimore). 2018 Nov;97(48):e13158. PMID: 30508894; PMCID: PMC6283129. doi: https://doi.org/10.1097/MD.0000000000013158
Kulik EM. Thurnheer T. Karygianni L. Walter C. Sculean A. Eick S. Antibiotic Susceptibility Patterns of Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis Strains from Different Decades. Antibiotics (Basel). 2019 Dec 6;8(4):253. PMID: 31817588; PMCID: PMC6963212. doi: https://doi.org/10.3390/antibiotics8040253
Invernici MM. Salvador SL. Silva PHF. Soares MSM. Casarin R. Palioto DB. Souza SLS. Taba M Jr. Novaes AB Jr. Furlaneto FAC. Messora MR. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: A randomized clinical trial. J Clin Periodontol. 2018 Oct;45(10):1198-210. Epub 2018 Sep 24. PMID: 30076613; PMCID: PMC6221043. doi: https://doi.org/10.1111/jcpe.12995.
Haque M. Sartelli M. Haque SZ. Dental Infection and Resistance-Global Health Consequences. Dent J (Basel). 2019 Mar 1;7(1):22. PMID: 30823670; PMCID: PMC6473604. doi: https://doi.org/10.3390/dj7010022
Könönen E. Gursoy M. Gursoy UK. Periodontitis: A Multifaceted Disease of Tooth-Supporting Tissues. J Clin Med. 2019 Jul 31;8(8):1135. PMID: 31370168; PMCID: PMC6723779. doi: https://doi.org/10.3390/jcm8081135
Kornman KS. Contemporary approaches for identifying individual risk for periodontitis. Periodontol 2000. 2018 Oct;78(1):12-29. PMID: 30198138. doi: https://doi.org/10.1111/prd.12234
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2020 Медичні перспективи
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.